An Evaluation of the Effectiveness and Tolerability of Tapentadol Hydrochloride Prolonged Release, and Tapentadol Hydrochloride Immediate Release on Demand, in Subjects With Severe Chronic Pain Due to Osteoarthritis of the Knee Taking WHO Step III Analgesics But Showing a Lack of Tolerability.
Latest Information Update: 22 Oct 2019
Price :
$35 *
At a glance
- Drugs Tapentadol (Primary) ; Tapentadol (Primary)
- Indications Pain
- Focus Registrational; Therapeutic Use
- Sponsors Grunenthal
- 18 Feb 2019 This trial has been completed in Spain, according to European Clinical Trials Database.
- 02 May 2012 According to the European Clinical Trials Database, this trial is completed in the United Kingdom (Jun 2010), Germany (Aug 2010) and Denmark, and is still recruiting in Spain. According to the ClinicalTrials.gov record, this trial has been discontinued.
- 02 May 2012 New source identified and integrated (European Clinical Trials Database).